Carboxyamidotriazole
- Generic Name
- Carboxyamidotriazole
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H12Cl3N5O2
- CAS Number
- 99519-84-3
- Unique Ingredient Identifier
- 6ST3ZF52WB
- Background
Carboxyamidotriazole has been used in trials studying the treatment of Lymphoma, Lung Cancer, Breast Cancer, Kidney Cancer, and Ovarian Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
- Conditions
- Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma
- Interventions
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00004146
- Locations
- ๐บ๐ธ
University of Alabama Birmingham, Birmingham, Alabama, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
๐บ๐ธEmory University/Winship Cancer Institute, Atlanta, Georgia, United States
Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00003249
- Locations
- ๐บ๐ธ
University of Chicago Cancer Research Center, Chicago, Illinois, United States
Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer
- Conditions
- Recurrent Renal Cell CancerStage IV Renal Cell Cancer
- Interventions
- Drug: carboxyamidotriazoleOther: placebo
- First Posted Date
- 2003-07-28
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 335
- Registration Number
- NCT00006486
- Locations
- ๐บ๐ธ
Cancer and Leukemia Group B, Chicago, Illinois, United States
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019461
- Locations
- ๐บ๐ธ
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer
- Conditions
- Stage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerStage IIIA Non-small Cell Lung Cancer
- Interventions
- Drug: carboxyamidotriazoleOther: placeboProcedure: quality-of-life assessmentOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 186
- Registration Number
- NCT00003869
- Locations
- ๐บ๐ธ
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.